Diversity in action! Our global ERG communities met recently at our Basel campus for a transformative three-day summit. Leaders from across the world connected to inspire, learn from and empower each other. With 70+ ERGs focusing on gender, LGBTQI+, race, culture, ethnicity, environment, disability, well-being and veterans, we're not just talking diversity – we're living it. With Novartis leadership and our DEI & Culture teams, #ERGGlobalSummit2024 featured dynamic panel discussions, inspiring speakers, and a pop-up coffee lounge to fuel conversations and ideas. Watch the highlights and collective inspiration in action. #NovartisERGSummit #InspiredCuriousUnbossed
About us
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
- Website
-
http://www.novartis.com
External link for Novartis
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Basel, Baselstadt
- Type
- Public Company
- Specialties
- Cardiovascular, Immunology, Neuroscience, Solid Tumors, Hematology, Chemistry, xRNA, Radioligand, and Gene and cell therapy
Locations
Employees at Novartis
-
Guy Dickinson
Figuring out #FutureOfWork: GenerativeAi + Employee Experience + Behavioural Design + Capability Building + Digital Skills
-
David Yee
Head Portfolio Systems, Portfolio Strategy & Analytics, Strategy & Growth at Novartis
-
Rodolfo Garcia de Alba Cassaigne
Regional Category Procurement Director, US Marketing Agencies
-
Kelley Dallas Priddy, M.S.
Medical Sales Specialist | Award Winner | Drives Sales Performance Through Analytics & Business Planning
Updates
-
The path to helping people living with disease is a complex one; full of challenges that can only be overcome with curiosity, determination and the support of a strong, united team. At Novartis, that means going beyond ourselves and reaching out to involve others at all stages of the drug development process. Silvana is one of our Preclinical Safety experts, who epitomises how curiosity and passion align with collaboration to push the limits of what's possible. Learn more here: https://lnkd.in/g48E9Dyt #Novartis #ThriveTogether #NovartisCareers
-
#RadioligandTherapy (RLT) represents a different frontier in treating advanced cancers. We are investing in every aspect of RLT to expand our ability to deliver to patients not just today—but into the future. With an expanding global footprint, industry-leading supply chain and a clear vision for this treatment paradigm, we are fully committed to the present—and future—of RLTs. Go #BehindTheGlassAtNVS to learn more: https://lnkd.in/gJ7g_VpU
-
We are where we are today because people believed things were possible. Like eliminating a disease. The progress we have made against malaria in the past 25 years is nothing short of extraordinary. But we’re not done yet – with over 600,000 people still dying each year from this disease. We need to come together to finally outsmart the mosquito. It’s our responsibility. #WorldMalariaDay
-
It’s been a great start to the year as we continue momentum across our business and pipeline. Our people have driven progress in innovation, led performance across all key brands and geographies, demonstrated operational and financial strength, which has led to continued confidence in our mid- and long-term growth outlook. Our purpose to reimagine medicine to improve and extend people’s lives can be seen through passion and dedication, as we work with healthcare, partners, caregivers, and patients. If you are interested in our business progress, more information can be found for Q1 Earnings here: Press release: https://lnkd.in/edaFyr-n Investor relations deck: https://lnkd.in/eYcSeBKW
-
IgA nephropathy (IgAN) – a progressive, rare kidney disease – is particularly hard to diagnose. Individuals in the early stages of the disease often don’t show symptoms, resulting in many patients receiving a diagnosis after they have already experienced significant kidney damage. Learn more about the signs and symptoms of IgAN: https://lnkd.in/gfVpQhEQ
-
IgA nephropathy (IgAN) is a progressive, rare kidney disease; each year, approximately 25 people worldwide are newly diagnosed with IgAN. Click here to learn more about the causes, signs and symptoms of IgAN: https://lnkd.in/g7B4ghks
-
People living with rare kidney diseases, such as IgA nephropathy (IgAN), can experience fear and anxiety about disease progression and the potential need for kidney dialysis or transplant. To learn more about the impact of IgAN, visit our website: https://lnkd.in/gB9A_jxX
-
Every step of our #RadioligandTherapy (RLT) manufacturing process reflects our deep commitment to delivering a transparent patient and prescriber experience. We strive for seamless and high-touch delivery—working to enable every person who needs these treatments to receive them at the speed they need them. Learn more #BehindTheGlassAtNVS: https://lnkd.in/gGHeymXn
-
IgA nephropathy (IgAN) is a progressive, rare kidney disease. Annually, around 25 people per million worldwide are newly diagnosed with IgAN. Unfortunately, current treatment options for patients fail to address the underlying causes of IgAN. To learn more about IgAN and Novartis commitment in addressing the unmet needs, visit our website: https://lnkd.in/gF2xpyzQ
Affiliated pages
Similar pages
Browse jobs
Stock
NVS
NYSE
20 minutes delay
$102.10
1.89 (1.886%)
- Open
- 101.13
- Low
- 101.04
- High
- 102.14
Data from Refinitiv
See more info on